Jelinek Herbert FJamil Dina AAubaidy Hayder A Al2016-03-112016-03-112014-11-21Jelinek Herbert F,Jamil Dina A, Aubaidy Hayder A Al. Impaired Fasting Glucose & 8-Iso- Prostaglandin F2a in Diabetes Disease Progression. British Journal of Medicine and Medical Research. 2014 Nov; 4(33): 5229-5237.http://imsear.searo.who.int/handle/123456789/175676Aims: The objective of the present study was to evaluate the changes of 8- isoprostaglandin F2α and other markers of oxidative stress with impaired fasting glucose when compared to non-diabetic control participants. Methodology: This is a cross-sectional study, conducted at Charles Sturt University, Albury, NSW, Australia and included 428 participants (female: male, 247:181) participants attending the Diabetes Complications Clinic in the School of Community Health for the period between January 2011 to October 2012. Results: Urinary 8-isoprostaglandin F2α was significantly greater in the impaired fasting glucose group (1.4±1.3ng/ml) compared to control group (0.68±0.5ng/ml, P= .05). The increase in urinary 8-isoprostaglandin F2α was associated with a significant elevation in serum total cholesterol (4.7±1.1mol/L, P= .04) and a significant reduction in high density lipoprotein cholesterol (1.4±0.4mmol/L, P= .02) in the impaired fasting glucose group compared to the control group. A significant negative correlation was noted between urinary 8-isoprostaglandin F2α and high-density lipoprotein cholesterol among all the participants included in this study (P= .05). Conclusions: The current study proves the importance of measuring markers of oxidative stress, expressed by urinary 8-isoprostaglandin F2α and serum lipids in managing cases of impaired fasting glucose and suggests a useful biomarker for assessing disease progression and/or remission, especially in the prediabetic state.enOxidative stressimpaired fasting glucose8-isoprostaglandin F2αserum lipidsArticle